目的探讨注射用红花黄色素联合阿加曲班治疗急性脑梗死的临床疗效。方法选取2014年9月—2015年9月西安医学院第二附属医院收治的急性脑梗死患者96例,依据不同治疗方案分为治疗组和对照组,每组各48例。所有患者均给予降低颅内压、营养神...目的探讨注射用红花黄色素联合阿加曲班治疗急性脑梗死的临床疗效。方法选取2014年9月—2015年9月西安医学院第二附属医院收治的急性脑梗死患者96例,依据不同治疗方案分为治疗组和对照组,每组各48例。所有患者均给予降低颅内压、营养神经、调节血脂等基础治疗。对照组在此基础上给予阿加曲班注射液,第1~2天,阿加曲班注射液60mg加入生理盐水500 m L,24 h持续泵入;其后5 d,阿加曲班注射液10 mg加入生理盐水100 m L,3 h持续泵入,2次/d,第8~14天,1次/d。治疗组在对照组的基础上滴注注射用红花黄色素,100 m L/次,1次/d。两组均连续治疗2周。观察两组临床疗效,同时比较两组神经功能缺损量表（NIHSS）评分、Barthel指数、血液流变学指标和血管内皮功能及炎症因子变化情况。结果治疗后,对照组和治疗组总有效率分别为77.08%、91.67%,两组比较差异有统计学意义（P〈0.05）。治疗后,两组血浆黏度、全血黏度、红细胞压积（HCT）以及红细胞聚集指数（RF）均显著降低,同组治疗前后比较差异具有统计学意义（P〈0.05）;且治疗后治疗组这些观察指标显著低于对照组,两组比较差异具有统计学意义（P〈0.05）。治疗后,两组NIHSS评分均降低,Barthel指数均升高,同组治疗前后比较差异具有统计学意义（P〈0.05）;且治疗2周后治疗组这些观察指标显著好于对照组,两组比较差异具有统计学意义（P〈0.05）。治疗后,两组一氧化氮（NO）、内皮素-1（ET-1）、白细胞介素-8（IL-8）和肿瘤坏死因子α（TNF-α）表达水平均较治疗前明显改善,同组治疗前后比较差异具有统计学意义（P〈0.05）;且治疗2周后治疗组这些观察指标显著好于对照组,两组比较差异具有统计学意义（P〈0.05）。结论注射用红花黄色素联合阿加曲班治疗急性脑梗死具有较好的临床疗效,能明显改善患者的血液流变学指标�展开更多
康复护理是康复医学不可分割的重要组成部分,包括一般护理和专科护理,其最终目的是最大限度地恢复患者的生活自理能力,重建患者身心平衡,健康地重返社会。Barthel指数评分量表主要评估患者的日常生活能力( Activities of daily living,A...康复护理是康复医学不可分割的重要组成部分,包括一般护理和专科护理,其最终目的是最大限度地恢复患者的生活自理能力,重建患者身心平衡,健康地重返社会。Barthel指数评分量表主要评估患者的日常生活能力( Activities of daily living,A D L ),是目前评估A D L 能力的最为公认、最常用的量表[1],该量表信度与效度已被国内外的研究充分验证[23]。它不仅可以用来评定患者治疗前后的功能状况,还可以预测治疗结果及预后效果,在康复医学中被广泛使用。本文就近年来Barthel指数评定表在康复护理中的应用现状综述如下。展开更多
目前缺血性脑卒中常用量表广泛应用于临床及科研中,了解和使用这些量表成为现在神经科医生不可缺少的工作内容。本文主要介绍目前临床常用的脑卒中相关量表,包括ABCD2评分、美国国立卫生研究院卒中量表(national institute of health st...目前缺血性脑卒中常用量表广泛应用于临床及科研中,了解和使用这些量表成为现在神经科医生不可缺少的工作内容。本文主要介绍目前临床常用的脑卒中相关量表,包括ABCD2评分、美国国立卫生研究院卒中量表(national institute of health stroke scale,NIHSS)、Rankin修订量表(mRS)和Barthel指数量表及其他卒中相关量表。展开更多
Cattle encephalon glycoside and ignotin(CEGI)injection is a compound preparation formed by a combination of muscle extract from hea lthy rabbits and brain gangliosides from cattle,and it is generally used as a neuropr...Cattle encephalon glycoside and ignotin(CEGI)injection is a compound preparation formed by a combination of muscle extract from hea lthy rabbits and brain gangliosides from cattle,and it is generally used as a neuroprotectant in the treatment of central and peripheral nerve injuries.However,there is still a need for high-level clinical evidence from large samples to support the use of CEGI.We therefore carried out a prospective,multicenter,randomized,double-blind,parallel-group,placebo-controlled study in which we recruited 319 patients with acute cerebral infarction from 16 centers in China from October 2013 to May 2016.The patients were randomized at a 3:1 ratio into CEGI(n=239;155 male,84 female;61.2±9.2 years old)and placebo(n=80;46 male,34 female;63.2±8.28 years old)groups.All patients were given standard care once daily for 14 days,including a 200 mg aspirin enteric-coated tablet and 20 mg atorvastatin calcium,both taken orally,and intravenous infusion of 250–500 mL 0.9%sodium chloride containing 40 mg sodium tanshinone IIA sulfonate.Based on conventional treatment,patients in the CEGI and placebo groups were given 12 mL CEGI or 12 mL sterile water,respectively,in an intravenous drip of 250 mL 0.9%sodium chloride(2 mL/min)once daily for 14 days.According to baseline National Institutes of Health Stroke Scale scores,patients in the two groups were divided into mild and moderate subgroups.Based on the modified Rankin Scale results,the rate of patients with good outcomes in the CEGI group was higher than that in the placebo group,and the rate of disability in the CEGI group was lower than that in the placebo group on day 90 after treatment.In the CEGI group,neurological deficits were decreased on days 14 and 90 after treatment,as measured by the National Institutes of Health Stroke Scale and the Barthel Index.Subgroup analysis revealed that CEGI led to more significant improvements in moderate stroke patients.No drug-related adverse events occurred in the CEGI or placebo groups.In conclusion,CEGI may be a 展开更多
文摘目的探讨注射用红花黄色素联合阿加曲班治疗急性脑梗死的临床疗效。方法选取2014年9月—2015年9月西安医学院第二附属医院收治的急性脑梗死患者96例,依据不同治疗方案分为治疗组和对照组,每组各48例。所有患者均给予降低颅内压、营养神经、调节血脂等基础治疗。对照组在此基础上给予阿加曲班注射液,第1~2天,阿加曲班注射液60mg加入生理盐水500 m L,24 h持续泵入;其后5 d,阿加曲班注射液10 mg加入生理盐水100 m L,3 h持续泵入,2次/d,第8~14天,1次/d。治疗组在对照组的基础上滴注注射用红花黄色素,100 m L/次,1次/d。两组均连续治疗2周。观察两组临床疗效,同时比较两组神经功能缺损量表（NIHSS）评分、Barthel指数、血液流变学指标和血管内皮功能及炎症因子变化情况。结果治疗后,对照组和治疗组总有效率分别为77.08%、91.67%,两组比较差异有统计学意义（P〈0.05）。治疗后,两组血浆黏度、全血黏度、红细胞压积（HCT）以及红细胞聚集指数（RF）均显著降低,同组治疗前后比较差异具有统计学意义（P〈0.05）;且治疗后治疗组这些观察指标显著低于对照组,两组比较差异具有统计学意义（P〈0.05）。治疗后,两组NIHSS评分均降低,Barthel指数均升高,同组治疗前后比较差异具有统计学意义（P〈0.05）;且治疗2周后治疗组这些观察指标显著好于对照组,两组比较差异具有统计学意义（P〈0.05）。治疗后,两组一氧化氮（NO）、内皮素-1（ET-1）、白细胞介素-8（IL-8）和肿瘤坏死因子α（TNF-α）表达水平均较治疗前明显改善,同组治疗前后比较差异具有统计学意义（P〈0.05）;且治疗2周后治疗组这些观察指标显著好于对照组,两组比较差异具有统计学意义（P〈0.05）。结论注射用红花黄色素联合阿加曲班治疗急性脑梗死具有较好的临床疗效,能明显改善患者的血液流变学指标�
文摘康复护理是康复医学不可分割的重要组成部分,包括一般护理和专科护理,其最终目的是最大限度地恢复患者的生活自理能力,重建患者身心平衡,健康地重返社会。Barthel指数评分量表主要评估患者的日常生活能力( Activities of daily living,A D L ),是目前评估A D L 能力的最为公认、最常用的量表[1],该量表信度与效度已被国内外的研究充分验证[23]。它不仅可以用来评定患者治疗前后的功能状况,还可以预测治疗结果及预后效果,在康复医学中被广泛使用。本文就近年来Barthel指数评定表在康复护理中的应用现状综述如下。
文摘目前缺血性脑卒中常用量表广泛应用于临床及科研中,了解和使用这些量表成为现在神经科医生不可缺少的工作内容。本文主要介绍目前临床常用的脑卒中相关量表,包括ABCD2评分、美国国立卫生研究院卒中量表(national institute of health stroke scale,NIHSS)、Rankin修订量表(mRS)和Barthel指数量表及其他卒中相关量表。
文摘Cattle encephalon glycoside and ignotin(CEGI)injection is a compound preparation formed by a combination of muscle extract from hea lthy rabbits and brain gangliosides from cattle,and it is generally used as a neuroprotectant in the treatment of central and peripheral nerve injuries.However,there is still a need for high-level clinical evidence from large samples to support the use of CEGI.We therefore carried out a prospective,multicenter,randomized,double-blind,parallel-group,placebo-controlled study in which we recruited 319 patients with acute cerebral infarction from 16 centers in China from October 2013 to May 2016.The patients were randomized at a 3:1 ratio into CEGI(n=239;155 male,84 female;61.2±9.2 years old)and placebo(n=80;46 male,34 female;63.2±8.28 years old)groups.All patients were given standard care once daily for 14 days,including a 200 mg aspirin enteric-coated tablet and 20 mg atorvastatin calcium,both taken orally,and intravenous infusion of 250–500 mL 0.9%sodium chloride containing 40 mg sodium tanshinone IIA sulfonate.Based on conventional treatment,patients in the CEGI and placebo groups were given 12 mL CEGI or 12 mL sterile water,respectively,in an intravenous drip of 250 mL 0.9%sodium chloride(2 mL/min)once daily for 14 days.According to baseline National Institutes of Health Stroke Scale scores,patients in the two groups were divided into mild and moderate subgroups.Based on the modified Rankin Scale results,the rate of patients with good outcomes in the CEGI group was higher than that in the placebo group,and the rate of disability in the CEGI group was lower than that in the placebo group on day 90 after treatment.In the CEGI group,neurological deficits were decreased on days 14 and 90 after treatment,as measured by the National Institutes of Health Stroke Scale and the Barthel Index.Subgroup analysis revealed that CEGI led to more significant improvements in moderate stroke patients.No drug-related adverse events occurred in the CEGI or placebo groups.In conclusion,CEGI may be a
